The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients
Objective: This study analyzes the clinical characteristics of ALK-positive lung cancer patients and the impact of PD-L1 expression on their prognosis, providing insights for diagnosis and treatment. Materials and methods: A total of 291 ALK-positive lung cancer patients, tested for PD-L1 expression...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294225000061 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective: This study analyzes the clinical characteristics of ALK-positive lung cancer patients and the impact of PD-L1 expression on their prognosis, providing insights for diagnosis and treatment. Materials and methods: A total of 291 ALK-positive lung cancer patients, tested for PD-L1 expression at the First Affiliated Hospital of Soochow University between January 2019 and November 2021, were included. Clinical data and prognostic information were collected. Statistical analysis was conducted using SPSS 26.0 to explore the relationship between clinical features and prognosis. Results: In ALK positive patients, the PD-L1 positivity rate was 59.8 %, with 19.2 % showing strong positivity. PD-L1 positive patients were predominantly male, over 55 years old, and presented more clinical symptoms, higher Ki-67 expression, larger tumor sizes, and more advanced disease stages. The progression-free survival (PFS) and overall survival (OS) were significantly lower in the ALK+PD-L1+ group compared to the ALK+PD-L1- group. Those receiving targeted therapy in stage IIIB-IVB non-squamous non-small cell lung cancer had significantly higher PFS and OS. Conclusion: PD-L1 positivity is common in ALK-positive lung cancer patients and correlates with poorer prognosis. PD-L1 serves as an independent predictor of adverse outcomes, indicating its potential as a biomarker for assessing lung cancer severity and prognosis. |
|---|---|
| ISSN: | 2468-2942 |